Voluntary Faculty
Voluntary faculty are typically clinicians or others who are employed outside of the School but make significant contributions to department programs at the medical center or at affiliate institutions.
Voluntary rank detailsJohn L Vaughn, MD, MS
Assistant Clinical ProfessorDownloadHi-Res Photo
About
Copy Link
Biography
John Vaughn is an Assistant Clinical Professor of Medicine. He received his medical degree from Ohio State University. He completed a residency in Internal Medicine at Ohio State University. He completed a fellowship in Hematology & Medical Oncology at NewYork-Presbyterian Weill Cornell Medical Center. He completed a fellowship in Bone Marrow Transplantation at Memorial Sloan Kettering Cancer Center. As a hospitalist, Dr. Vaughn's clinical practice focuses on the management of hospitalized patients with hematologic malignancies, including those receiving bone marrow transplants and cellular therapies. His research focus includes health services and outcomes research. He has a particular interest in the epidemiology of lymphoid malignancies. He participates in the education of medical students through the Yale Interprofessional Longitudinal Clinical Experience.
Last Updated on July 12, 2023.
Appointments
Internal Medicine
Assistant Clinical ProfessorPrimary
Other Departments & Organizations
Education & Training
- Fellow
- Memorial Sloan Kettering Cancer Center (2022)
- Fellow
- NewYork-Presbyterian Weill Cornell Medical Center (2021)
- MS
- Cornell University, Clinical Epidemiology & Health Services Research (2021)
- Resident
- The Ohio State University (2017)
- MD
- The Ohio State University (2014)
Research
Copy Link
Overview
Medical Research Interests
Epidemiology; Health Services Research; Lymphoma
ORCID
0000-0001-8122-3852
Research at a Glance
Yale Co-Authors
Frequent collaborators of John L Vaughn's published research.
Publications Timeline
A big-picture view of John L Vaughn's research output by year.
Research Interests
Research topics John L Vaughn is interested in exploring.
Jensa Morris, MD
Bonnie E Gould Rothberg, MD, PhD, MPH, MMM, FACP
Deborah Doroshow, MD, PhD
Elizabeth Horn Prsic, MD
Shalin Kothari, MD
Tarsheen Sethi, MD, MSc
17Publications
62Citations
Publications
2025
CD19 Directed CAR T Therapy for Transformed Follicular Lymphoma: A CIBMTR Analysis
Thiruvengadam S, Ahn K, Patel J, Lian Q, Hertzberg M, Epperla N, Metheny L, Hong S, Jain T, Aljurf M, Beitinjaneh A, Vaughn J, Gopal A, Iqbal M, Wirk B, Manjappa S, Oliver C, Mohty R, Shadman M, Turtle C, Hamadani M, Herrera A. CD19 Directed CAR T Therapy for Transformed Follicular Lymphoma: A CIBMTR Analysis. American Journal Of Hematology 2025, 100: 1803-1812. PMID: 40762207, DOI: 10.1002/ajh.70027.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsTransformed follicular lymphomaNon-relapse mortalityProgression-free survivalCAR-T infusionCAR-T therapyCytokine release syndromeCAR-TOverall survivalFollicular lymphomaT therapyCumulative incidenceCD19-directed chimeric antigen receptor T cellsCenter for International Blood and Marrow Transplant Research registryT infusionAssociated with inferior progression-free survivalChimeric antigen receptor T cellsCD19 CAR-T therapyCumulative incidence of relapseInferior progression-free survivalRisk of non-relapse mortalityAssociated with chemotherapy resistanceMedian prior linesCD19-CAR-TIncidence of relapseAxicabtagene ciloleucelAssociation of CAR-T approval on outcomes in patients with diffuse large B-cell lymphoma at the population level in the United States
Vaughn J, Ramdhanny A, Munir M, Rimmalapudi S, Epperla N. Association of CAR-T approval on outcomes in patients with diffuse large B-cell lymphoma at the population level in the United States. Biomarker Research 2025, 13: 64. PMID: 40275414, PMCID: PMC12023351, DOI: 10.1186/s40364-025-00780-4.Peer-Reviewed Original ResearchCitationsConceptsLymphoma-specific survivalOverall survivalCAR-TRelative survivalChimeric antigen receptor T cellsDiffuse large B-cell lymphomaLarge B-cell lymphomaCumulative incidence of deathB-cell lymphomaPopulation-based cohort studyReceipt of chemotherapyIncidence of deathPeriod of diagnosisRefractory DLBCLB symptomsMultivariate survival modelsMedian ageT cellsImproved survivalCumulative incidenceSEER-17Disease courseCohort studyDisease stageFDA approvalInpatient Immunotherapy Outcomes Study: A Multicenter Retrospective Analysis
Riaz F, Vaughn J, Zhu H, Dickerson J, Sayegh H, Brongiel S, Baldwin E, Kier M, Zaemes J, Hearn C, Abdelghany O, Cohen R, Parikh R, Reuss J, Prsic E, Doroshow D. Inpatient Immunotherapy Outcomes Study: A Multicenter Retrospective Analysis. JCO Oncology Practice 2025, 21: 1165-1173. PMID: 39937997, DOI: 10.1200/op-24-00788.Peer-Reviewed Original ResearchCitationsAltmetricConceptsImmune checkpoint inhibitorsOverall survivalICI administrationSolid malignanciesPatients treated with immune checkpoint inhibitorsAdministration of immune checkpoint inhibitorsMultivariate Cox proportional hazards model analysisResponse to ICI therapyCox proportional hazards model analysisProportional hazards model analysisAdvanced solid malignanciesKaplan-Meier methodOutcomes of patientsInstitutional electronic medical recordsHazards model analysisCox proportional hazards modelsProportional hazards modelCheckpoint inhibitorsICI therapyMedian OSICI initiationICI useRetrospective studyClinical outcomesClinicodemographic variables
2024
A comparative analysis of transformed indolent lymphomas and de novo diffuse large B-cell lymphoma: a population-based cohort study
Vaughn J, Ramdhanny A, Munir M, Rimmalapudi S, Epperla N. A comparative analysis of transformed indolent lymphomas and de novo diffuse large B-cell lymphoma: a population-based cohort study. Blood Cancer Journal 2024, 14: 212. PMID: 39609401, PMCID: PMC11604794, DOI: 10.1038/s41408-024-01194-5.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsIndolent non-Hodgkin lymphomaLymphoma-specific survivalDe novo DLBCLOverall survivalIndolent lymphomaT-FLHistological transformationRelative survivalDe novo diffuse large B-cell lymphomaIndolent non-Hodgkin's lymphoma subtypesDiffuse large B-cell lymphomaReceipt of prior chemotherapyAssociated with inferior survivalLarge B-cell lymphomaMedian follow-up timeStudy of adult patientsLymphoplasmacytic lymphoma/Waldenstrom macroglobulinemiaTransformed indolent lymphomaMarginal zone lymphomaNon-Hodgkin's lymphomaB-cell lymphomaTransformed follicular lymphomaIncidence of HTPopulation-based cohort studyPopulation-based studyImpact of Chimeric Antigen Receptor T-Cell Therapy on Survival in Patients with Diffuse Large B-Cell Lymphoma at the Population Level in the United States
Ramdhanny A, Vaughn J, Epperla N. Impact of Chimeric Antigen Receptor T-Cell Therapy on Survival in Patients with Diffuse Large B-Cell Lymphoma at the Population Level in the United States. Blood 2024, 144: 3745. DOI: 10.1182/blood-2024-211747.Peer-Reviewed Original ResearchConceptsDiffuse large B-cell lymphomaCAR-T cell therapyT-cell therapyChimeric antigen receptorChimeric antigen receptor T-cell therapyPresence of B symptomsLarge B-cell lymphomaB-cell lymphomaOverall survivalFood and Drug AdministrationRelative survivalB symptomsApproval of CAR-T cell therapyAdvent of chimeric antigen receptorCentral nervous system lymphomaMultivariable flexible parametric survival modelNervous system lymphomaMedian Follow-UpUS Food and Drug AdministrationPopulation-based cohort studySurveillance, EpidemiologyPeriod of diagnosisUS populationPersons per yearP-value <Trends in Incidence and Survival of Patients with Primary Effusion Lymphoma in the United States
Vaughn J, Epperla N. Trends in Incidence and Survival of Patients with Primary Effusion Lymphoma in the United States. Blood 2024, 144: 5119. DOI: 10.1182/blood-2024-211851.Peer-Reviewed Original ResearchConceptsSurvival of patientsPrimary effusion lymphomaOverall survivalAnnual percent changeB symptomsAssociated with HIV infectionEffusion lymphomaTreatment of PELPopulation-based cohort study of patientsRelative survivalCohort study of patientsIncidence rateFive-year OSMedian Follow-UpFive-year RSWorld Health OrganizationPopulation-based cohort studyAge-adjusted incidence ratesCalculate annual percent changesStudy of patientsPatients to clinical trialsTreatment of HIVPeriod of diagnosisFlexible parametric survival modelsDA-EPOCHEvaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation
Epperla N, Huang Y, Cashen A, Vaughn J, Hanel W, Badar T, Barta S, Caimi P, Sethi T, Reddy N, Karmali R, Bello C, Chavez J, Kothari S, Hernandez-Ilizaliturri F, Svoboda J, Lansigan F, Glenn M, Cohen J, Sorge C, Christian B, Herrera A, Hamadani M, Costa L, Xavier A. Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation. Blood Advances 2024, 8: 5458-5466. PMID: 39213424, PMCID: PMC11532746, DOI: 10.1182/bloodadvances.2024013743.Peer-Reviewed Original ResearchCitationsAltmetricConceptsPrimary treatment failureAuto-HCTStable diseaseHodgkin lymphomaPartial responseCumulative incidence of non-relapse mortalityIncidence of non-relapse mortalityAssociated with inferior PFSEfficacy of auto-HCTAssociated with inferior OSAutologous hematopoietic cell transplantationEvaluation of prognostic factorsClassical Hodgkin lymphomaNon-relapse mortalityMulticenter retrospective cohortHigh-risk diseaseHematopoietic cell transplantationLong-term efficacyPatterns of failureUS medical centersProgression of diseaseInferior PFSMedian PFSInferior OSComplete responseAssociation of Hospitalist Care and Outcomes for Patients Electively Admitted for Chemotherapy
Vaughn J, Morris J, Merl M, Gould Rothberg BE. Association of Hospitalist Care and Outcomes for Patients Electively Admitted for Chemotherapy. Journal Of Brown Hospital Medicine 2024, 3: 115906. PMID: 40026792, PMCID: PMC11864383, DOI: 10.56305/001c.115906.Peer-Reviewed Original ResearchConceptsLength of stayAnticancer therapyHematologic malignanciesHospitalist careBlood cell count recoveryTumor lysis syndromeQuality outcomesMean discharge timeEfficiency of careOutcomes of length of stayMixed linear regression modelsCount recoveryCare of patientsMethotrexate clearanceTherapy initiationTherapy regimenNo significant differenceTherapy administrationPatientsLinear regression modelsMean timeTherapySignificant differenceImprove qualityMalignancy
2023
Association of Hospitalist Care and Outcomes on an Inpatient Elective Anticancer Therapy Service
Vaughn J, Merl M, Morris J, Rothberg BE. Association of Hospitalist Care and Outcomes on an Inpatient Elective Anticancer Therapy Service. Blood 2023, 142: 2335. DOI: 10.1182/blood-2023-190824.Peer-Reviewed Original ResearchConceptsHospitalist careTherapy administrationRace/ethnicityTherapy servicesIllness indexSmilow Cancer HospitalTumor lysis syndromeMean discharge timeSignificant differencesQuality outcomesIndex regimenLysis syndromeMedian ageAnticancer regimenMultiple admissionsMethotrexate clearanceCancer HospitalCancer CenterTreatment daysTherapy typeDay 1PatientsAdmissionLymphomaTherapy team
2022
CD34-selected allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in the tyrosine kinase era
Vaughn J, Brown S, Papadopoulos E, Jakubowski A, Tamari R, Giralt S, Ponce D, Cho C, Perales M, Shaffer B, Gyurkocza B. CD34-selected allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in the tyrosine kinase era. Bone Marrow Transplantation 2022, 57: 1740-1742. PMID: 36076011, DOI: 10.1038/s41409-022-01783-7.Peer-Reviewed Original ResearchMeSH Keywords and Concepts